Pinealon (EDR)

Synthetic Tripeptide | Neuroprotection & Cognitive Enhancement

Weight: 418.4 Da
Half-life: Not established
Chain: 3 amino acids
4 studies
2021 latest
Well Studied
Dose Injectable: 5mg daily or 100-300mcg daily; Oral: 0.2mg twice daily
Frequency Injectable: daily for 20 days; Oral: morning and afternoon on empty stomach
Cycle 20 days per cycle
Storage Refrigerate at 2-8°C, use within 30 days after reconstitution

Community Research

Join others researching Pinealon — share findings, ask questions, and learn from real experiences

Developed in Russia, Pinealon demonstrates unique DNA-interaction for neuroprotection and cognitive enhancement. Benefits traumatic brain injury recovery and age-related cognitive decline with excellent safety profile.

Mechanism of Action

Penetrates nuclear membranes to directly interact with DNA, modulates gene expression via histone H1.3 binding and MAPK/ERK pathway activation.

01 Direct DNA interaction
02 Neuroprotection
03 Cognitive enhancement
04 Excellent safety profile
05 40+ years of clinical use in Russia

Molecular Data

Molecular Weight
418.4 Da
Chain Length
3 amino acids
Type
Tripeptide
Amino Acid Sequence
One-letter: ED?
H₂N
E 1
O C
N
D 2
O C
N
H
? 3
COOH
Glu
1

Glutamic Acid

Position 1

Asp
2

Aspartic Acid

Position 2

Arg
3

Arg (EDR)

Position 3

N-terminus C-terminus
Hydrophobic
Polar
Positive (+)
Negative (-)
Modified

Research Indications

Neuroprotection
Traumatic Brain Injury most effective

Clinical protocol of 5mg daily showed significant cognitive improvements in 72-patient study.

Direct CNS Delivery effective

Subcutaneous administration allows systemic circulation to brain tissue for neuroprotective effects.

Cellular Protection effective

Caspase-3 suppression, ROS reduction, and excitotoxicity protection.

Cognitive
Memory Enhancement effective

Enhanced neurotransmitter function with 1.9x serotonin increase in cell cultures.

NMDA Receptor Expression effective

100 ng/kg optimal dose improved spatial learning in hippocampus.

Anti-Aging
Cellular Senescence Reduction moderate

Irisin expression increases linked to telomere protection and mitochondrial enhancement.

Biological Age Markers moderate

32-patient study showed significant improvements in aging indicators over 20-30 days.

Dosing Protocols

Highest bioavailability, direct systemic delivery, established clinical protocols.

GoalDoseFrequencyRoute
Neuroprotection5mg dailyOnce dailySubQ
Cognitive Enhancement100-300mcgDaily or every other daySubQ
Anti-aging5mg20 days, 2-3x yearlySubQ

Reconstitution Instructions

Materials Needed:
  • Lyophilized Pinealon powder
  • Bacteriostatic water for injection
  • Insulin syringes (30-31 gauge)
  • Alcohol swabs
  1. 1 Remove powder and water from refrigeration
  2. 2 Clean vial tops with alcohol swabs; allow to dry
  3. 3 Draw bacteriostatic water into syringe
  4. 4 Inject water slowly down vial side to avoid foam
  5. 5 Gently swirl until completely dissolved
  6. 6 Store at 2-8°C
  7. 7 Use within 30 days

Interactions

++
Epitalon
Enhanced neuroprotection through complementary telomerase activation pathways.
synergistic
++
Cortexin
Synergistic cognitive recovery in stroke patients through brain region targeting.
synergistic
+
Thymalin
Safe combination supporting neural-immune axis optimization.
compatible
~
Melatonin
Monitor sleep patterns; Pinealon stimulates endogenous serotonin production.
monitor
+
BPC-157
Different mechanisms with no known interactions.
compatible
+
NAD+
Complementary anti-aging mechanisms.
compatible

What to Expect

Week 1-2
Improved mental clarity and focus
Week 2-3
Enhanced cognitive processing and memory
Week 3-4
Peak neuroprotective and anti-aging benefits

Side Effects & Safety

Common Side Effects

  • Minimal injection site reactions
  • Mild gastrointestinal adjustment
  • Occasional headache
  • Fatigue

Stop Signs - Discontinue if:

  • Severe headaches or mood changes
  • Persistent injection site reactions
  • Signs of infection at injection site
  • Unusual neurological symptoms
  • Allergic reactions

Contraindications

  • Pregnancy
  • Lactation

Quality Checklist

Good Signs

  • White crystalline powder; proper freeze-drying indicated
  • Clear reconstituted solution; no particles or cloudiness
  • Pharmaceutical packaging with batch numbers from reputable sources

Warning Signs

  • Ensure distinction between research (lab only) and pharmaceutical (human use) grade

Bad Signs

  • Discolored powder (yellow or brown) indicates degradation from heat or moisture
  • Cloudy solution indicates contamination

Frequently Asked Questions

Does Pinealon really interact directly with DNA, or is that marketing?

It's verified science, not marketing. Pinealon penetrates nuclear membranes and directly binds to histone H1.3 and DNA structures to modulate gene expression. Multiple peer-reviewed studies document this mechanism. It's one of the few peptides that works through direct DNA interaction rather than receptor binding.

Can I take Pinealon orally, or does it need injection?

Both work. Oral forms (0.2mg twice daily) use the 3-amino acid structure that survives stomach acid. Injection (5mg daily SubQ) offers higher bioavailability. Oral is more convenient, but injection provides direct systemic delivery. Choose based on convenience vs. guaranteed absorption preference.

Why is 40+ years of Russian clinical use relevant if it's not FDA-approved?

Russian clinical use demonstrates long-term safety data in thousands of patients—much more than most research peptides have. While it doesn't equal FDA approval, 40 years of safety documentation in clinical settings is meaningful evidence of tolerability. However, rigorous Western clinical trials remain absent.

How does Pinealon compare to P21 for brain protection?

Both target neuroprotection but work differently. Pinealon modulates MAPK/ERK pathways and increases serotonin (more mood support), while P21 increases BDNF and promotes neurogenesis (more cognitive/learning focus). Pinealon has clinical evidence; P21 is preclinical. Pinealon is better-established for TBI recovery.

References

  • Human Clinical Trial - Post-Traumatic Cerebrasthenia
    (2015)

    72 patients aged 30-74; 0.2mg twice daily; 20-30 days. Improved memory, reduced headache severity, and enhanced emotional stability compared to controls.

  • Aging Study - Polymorbidity Patients
    (2015)

    32 patients aged 41-83; variable dosing; 30 days. Significant improvements in biological aging biomarkers with anabolic effects.

  • Diabetic Rat Model - Spatial Learning
    (2020)

    100 ng/kg optimal dose; 14 days. Enhanced NMDA receptor expression in hippocampus with neuroplasticity improvements.

  • 5xFAD Alzheimer's Mouse Model
    (2021)

    400 μg/kg IP daily; 28 days. Prevention of dendritic spine loss through MAPK/ERK pathway modulation.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.